Searched for
CNS THERAPY
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Cardiac drugs log highest sales in 2025 as NCD cases surgeHeart medicines led sales in 2025, a trend set to continue. Respiratory and anti-diabetes drugs followed. Cardiac drug sales grew 13%, with...
- Cipla eyes entry into India's weight management market amid rising demand and global competitionCipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening it...
- Pfizer board approves marketing, supply pact with Mylan for two brandsPfizer Ltd's board has approved a five-year marketing and supply agreement with Mylan Pharmaceuticals for the brands Ativan and Pacitane, t...
- Pharma market in good health; lifestyle diseases may be risingThe other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the therapy segment, the...
- Engrail Therapeutics raises $157 million in funding from F-Prime Capital, othersThe proceeds of the fund raise will help to support advancement of Engrail’s pipeline for neuropsychiatric and neurodevelopmental disorders
- Drug sales show the times are bad for mental healthData sourced from market research firm AIOCD-AWACS show a 13% year-on-year jump in sales of CNS (central nervous system) drugs for the June...
- Torrent Pharma walks away with Unichem’s domestic business for Rs 3,600 croreThe deal will put Torrent among the country’s top five drugmakers. It will will also give Torrent access to 120 brands of Unichem in India ...
- Cipla eyes filing over 20 ANDAs in US this fiscalThe company said it will continue to focus on investing towards building its speciality franchise through a combination of development with...
- Suven Life gets patents for neuro-degenerative drugWith these new patents, Suven has a total of 24 granted patents from Australia, 17 from Eurasia and 9 from Israel and 24 from the US.
- Suven Life gets patent for neuro-degenerative drugSuven has been granted a patent each by Europe, Hong Kong, Japan, Macau, ARIPO and South Korea for a drug used in the treatment of neuro-de...
- Suven Life gets patent for neuro-degenerative drugWith these new patents, Suven has a total of 22 granted patents from Australia, 19 from China, 17 from Europe, 17 from South Korea and 23 f...
- Strides Arcolab gains as company acquires CNS divisions of erstwhile RanbaxyThe agreement involves transfer of these two marketing divisions, along with employees to Strides for a consideration of Rs 165 crore.
- Sun Pharma sells divisions of Ranbaxy to Strides Arcolab for Rs 165 croreAs part of the deal, India’s largest drug maker Sun Pharma will transfer two arms of Ranbaxy – Solus and Solus care – for a consideration o...
- Suven Life shares close 7.5% up on securing molecule patentThe stock surged 7.09 per cent to settle at Rs 252.20 on the BSE. During the day, it jumped 8.66 per cent to Rs 255.90.
- Suven Life gets patent for chemical molecules to be used in neuro-degenerative drugsIn a BSE filing, the company said that it 'secured patents from China and South Africa to the new chemical entities (NCE) for central nervo...
- Domestic Pharma Growth Improves for the month of MaySequentially, the domestic pharma industry staged an improvement for the month of May. At 9.9%, according to data compiled by PharmaTrac
- Ranbaxy Laboratories launches generic Olanzapine tablets in SpainRanbaxy has received necessary regulatory approvals from the Spanish health authorities to manufacture and market Olanzapine in Spain.
- Lupin's Japanese arm gets nod to sell 10 productsThe company plans to launch these products by July 2008. Lupin is the first Indian co to get approval from the Japanese drug authorities to...
- Lupin's Japanese arm gets nod for 10 productsLupin's Japanese subsidiary Kyowa Pharma has received approvals for 10 products and expects to launch these in July 2008 post NHI listing.
Load More
